Emily Jessie
Family · Scottsville, KYNPI 1306204490
Payments from drug & device makers
Across 236 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- AstraZeneca$743
- Novo Nordisk$622
- Mylan Specialty L.p.$215
- Lilly USA, LLC$197
- GSK$140
- plus $868 from 16 others
What the payments were for
- Food & beverage$3,547100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $761 |
| AstraZeneca | 31 | $743 |
| Novo Nordisk | 37 | $622 |
| Mylan Specialty L.p. | 13 | $215 |
| Lilly USA, LLC | 13 | $197 |
| GSK | 9 | $140 |
| Dexcom, Inc. | 8 | $137 |
| Boehringer Ingelheim | 8 | $117 |
| Novartis | 6 | $99 |
| Pfizer | 6 | $95 |
| Genentech USA, Inc. | 10 | $78 |
| Biohaven Pharmaceuticals, Inc. | 4 | $66 |
| Exact Sciences | 3 | $57 |
| Bayer | 3 | $53 |
| Amgen | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$124
How this compares
$3,547 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 69 | $57,587 |
| OzempicSemaglutide | 44 | $48,178 |
| TrulicityDulaglutide | 40 | $36,928 |
| MounjaroTirzepatide | 20 | $20,315 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,198 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $16,400 |
| Spiriva RespimatTiotropium Bromide | 28 | $15,306 |
| RybelsusSemaglutide | 12 | $14,869 |
| LinzessLinaclotide | 13 | $8,522 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $7,858 |
| MyrbetriqMirabegron | 11 | $4,968 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,736 |
| VascepaIcosapent Ethyl | 11 | $4,521 |
| Aripiprazole | 30 | $3,850 |
| SteglatroErtugliflozin Pidolate | 11 | $3,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $117 | $72,89397 claims |
| Novo NordiskOzempic, Rybelsus | $622 | $63,04756 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $197 | $57,24460 claims |
| GSKTrelegy Ellipta | $140 | $19,19830 claims |
| AbbVieLinzess | $761 | $8,52213 claims |
| AstraZenecaSymbicort | $743 | $7,85822 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $4,96811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Scottsville
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.